Study #2022-1065
NCI10590: NORM: nodular lymphocyte-predominant hodgkin lymphoma patients treated in a randomized phase 2 trial with either Rituximab or Mosunetuzumab
MD Anderson Study Status
Enrolling
Treatment Agent
Mosunetuzumab, Rituximab, Rituximab and Hyaluronidase Human
Description
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab may be more effective at extending survival in patients with NLPHL than the usual approach with rituximab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
Study phase:
Phase II
Physician name:
Dai Chihara
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.